SCP
CORT icon

Sivia Capital Partners’s Corcept Therapeutics CORT Stock Holding History

Sivia Capital Partners’s Portfolio CORT Stock Details CORT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$235K Buy
+2,702
New +$163K 0.03% 494

Other funds holding CORT

BTW
Boston Trust Walden Boston, Massachusetts $13.1B AUM 24.63% 1-Year Est. Return
New York State Teachers Retirement System (NYSTRS)
New York State Teachers Retirement System (NYSTRS) Albany, New York $54.2B AUM 43.77% 1-Year Est. Return
Wealth Enhancement Advisory Services
Wealth Enhancement Advisory Services Plymouth, Minnesota $59.8B AUM 29.42% 1-Year Est. Return
HWAM
Hennion & Walsh Asset Management Parsippany, New Jersey $3.5B AUM 41.95% 1-Year Est. Return
PFSRSONJ
Police & Firemen's Retirement System of New Jersey Trenton, New Jersey $13.3B AUM 45.46% 1-Year Est. Return
LSERS
Louisiana State Employees Retirement System Baton Rouge, Louisiana $6.74B AUM 53.06% 1-Year Est. Return
SOADOR
State of Alaska Department of Revenue Juneau, Alaska $10.1B AUM 42.83% 1-Year Est. Return
Handelsbanken Fonder
Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return
LTAS
Linden Thomas Advisory Services Charlotte, North Carolina $1.24B AUM 47.37% 1-Year Est. Return
ORI
Oak Ridge Investments Chicago, Illinois $1.77B AUM 63.16% 1-Year Est. Return

Sivia Capital Partners's CORT Position: Q2 2026 in Review

Sivia Capital Partners opened a new position in Corcept Therapeutics (CORT) in Q2 2026: 2,702 shares worth $235K. The stake represents 0.03% of the portfolio and ranks #494 among its holdings.

76 funds tracked by Wall St. Rank hold CORT as of Q2 2026.

  • Sivia Capital Partners held 2,702 shares of Corcept Therapeutics worth $235K as of Q2 2026.
  • Corcept Therapeutics was a new Sivia Capital Partners position in Q2 2026.
  • Corcept Therapeutics made up 0.03% of Sivia Capital Partners's portfolio in Q2 2026, its #494 holding.
  • 76 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q2 2026.

Based on Sivia Capital Partners's 13F filing for Q2 2026, filed 23 Jul 2026.